Can nattokinase be used to treat hypercholesterolemia, and what dosage (in fibrinolytic units) and safety precautions are recommended?

Nattokinase Should Not Be Used as Primary Therapy for Hypercholesterolemia

Nattokinase is not recommended for treating hypercholesterolemia based on current evidence-based guidelines, which universally recommend statins as first-line therapy for lipid management. 1, 2 The major cardiovascular guidelines make no mention of nattokinase, and the available research evidence is contradictory and insufficient to support its use for cholesterol reduction.

Guideline-Based Standard of Care

All major cardiovascular guidelines consistently recommend:

• Statins as first-line therapy for LDL-C lowering in patients requiring pharmacological treatment 1, 2
• Target LDL-C <100 mg/dL as the primary goal, with <70 mg/dL reasonable for very high-risk patients 1
• Therapeutic lifestyle changes including dietary modification (<7% saturated fat, <200 mg/day cholesterol), physical activity, and weight management 1
• Ezetimibe as second-line add-on therapy when statins alone are insufficient 1, 2
• PCSK9 inhibitors for patients who remain above target despite maximally tolerated statin plus ezetimibe 2, 3

Contradictory Research Evidence on Nattokinase

The research literature presents conflicting findings that preclude clinical recommendation:

Negative Evidence:

• The highest-quality study—a 3-year randomized controlled trial with 265 participants—found nattokinase 2,000 FU had zero effect on carotid intima-media thickness, arterial stiffness, blood pressure, or any lipid parameters 4. This directly contradicts claims of cardiovascular benefit.

Positive Evidence:

• One observational study (not randomized) with 1,062 participants reported improvements with 10,800 FU/day, but noted that 3,600 FU/day was completely ineffective 5
• A meta-analysis showed nattokinase at relatively low doses actually increased total cholesterol and LDL-C rather than lowering them 6

Critical Issues:

• Massive dose discrepancies (2,000 FU vs 10,800 FU) with no clear therapeutic window
• The positive study 5 was not blinded and lacked proper controls
• No long-term cardiovascular outcome data (mortality, MI, stroke)
• Safety data limited to short-term studies 7

Dosing Confusion and Safety Concerns

If nattokinase were to be considered (which it should not be for hypercholesterolemia):

• The dose of 2,000 FU/day showed no benefit 4
• The dose of 3,600 FU/day was ineffective 5
• The dose of 10,800 FU/day showed effects in one uncontrolled study 5
• This represents a 5-fold difference between ineffective and potentially effective doses

Safety precautions would theoretically include:

• Avoid in patients on anticoagulants or antiplatelet agents due to fibrinolytic activity
• Monitor for bleeding complications
• Contraindicated in bleeding disorders
• However, these are theoretical since nattokinase lacks FDA approval for any indication

Clinical Algorithm for Hypercholesterolemia

Step 1: Initiate therapeutic lifestyle changes (diet, exercise, weight management) 1

Step 2: Start moderate-to-high intensity statin therapy 1, 2

• Atorvastatin 40-80 mg or rosuvastatin 20-40 mg for high-intensity
• Atorvastatin 10-20 mg or rosuvastatin 5-10 mg for moderate-intensity

Step 3: If LDL-C remains ≥100 mg/dL on maximally tolerated statin, add ezetimibe 10 mg daily 1, 2

Step 4: If LDL-C remains ≥70 mg/dL (very high-risk patients) on statin plus ezetimibe, add PCSK9 inhibitor 2, 3

Step 5: For statin-intolerant patients, use ezetimibe and/or bile acid sequestrants 1

Nattokinase has no role in this algorithm.

Common Pitfalls

• Do not substitute unproven supplements for evidence-based statin therapy—this delays effective treatment and increases cardiovascular risk
• Do not be swayed by single positive observational studies when higher-quality RCTs show no benefit
• Do not assume "natural" products are safer or equally effective—statins have decades of outcome data showing mortality reduction
• Do not use nattokinase in patients on anticoagulation—the fibrinolytic activity creates bleeding risk without proven cardiovascular benefit

The evidence is clear: statins reduce cardiovascular events and mortality 1, 2. Nattokinase does not have this evidence base and showed no benefit in the best-designed trial 4.